Maryland Approves Medicaid Reimbursement for ActiPatch(R)
Other States May Soon Follow
FREDERICK, Md., April 21 // -- Maryland Medicaid has approved
medical necessity product reimbursement for ActiPatch(TM) for
kidney-compromised patients. BioElectronics Corporation, (Pink Sheets:
BIEL), is the maker of ActiPatch, a revolutionary drug-free
anti-inflammatory patch which accelerates healing.
Many commonly used pharmaceutical agents including aspirin, ibuprofen
(Advil, Motrin, Nuprin) and Naproxen (Aleve, Anaprox, Naprosyn) with
regular use and most especially long-term use, can have serious
complications such as ulcers and bleeding from the gastrointestinal tract.
These medications have been known to worsen cardiovascular conditions,
increase high blood pressure, kidney disease and diabetes.
Andrew J. Whelan, CEO of BioElectronics Corporation, explains,
"ActiPatch with its non-invasive, very efficient treatment for swelling and
pain while accelerating recovery is the medicine of the future available
today. We are actively pursuing additional reimbursement approvals
nationally. ActiPatch is an important product that not only works without
side-effects, it also has the potential to help keep medical costs down at
a time when medical and insurance costs appear to be spiraling out of
control," adds Whelan.
ActiPatch(TM) is a wafer thin patch with an embedded battery operated
microchip that delivers weeks of continuous pulsed RF therapy for less than
a dollar a day. The unique ActiPatch(TM) delivery system, using patented
technology, provides a cost-effective, home use method to reduce soft
tissue pain and swelling.
ActiPatch has regulatory clearance by the FDA for the treatment of
edema following blepharoplasty.
For more information visit http://www.bioelectronicscorp.com or call
866-757-2284.
About BioElectronics
BioElectronics Corporation is the maker of the ActiPatch(TM). ActiPatch
is a drug free anti-inflammatory patch with an embedded battery operated
microchip that delivers weeks of continuous pulsed therapy for less than a
dollar a day. The unique ActiPatch delivery system, using patented
technology, provides a cost-effective patient friendly method to reduce
soft tissue pain and swelling.
For more information visit: http://www.bioelectronicscorp.com.
Safe Harbor Statement
This news release contains forward-looking statements related to future
growth and earnings opportunities. Such statements are based upon certain
assumptions and assessments made by management in light of current
conditions, expected future developments and other factors it believes to
be appropriate. Actual results may differ as a result of factors over which
the company has no control.
Media Relations Contact:
Patricia Baker, The Big Picture Agency LLC
Voice: 413-623-0950 ext. 221, email: pbaker@bigpictureagency.com
Investor Relations Contact:
Joe Noel, Emerging Growth Research LLP
Voice: 925-922-2560, email: jnoel701@yahoo.com
|
